INJECTABLE GOLD COMPOUNDS: AN OVERVIEW
Identifieur interne : 002997 ( Main/Exploration ); précédent : 002996; suivant : 002998INJECTABLE GOLD COMPOUNDS: AN OVERVIEW
Auteurs : G. Jones ; P. M. Brooks [Australie]Source :
- Rheumatology [ 1462-0324 ] ; 1996.
Abstract
Injectable gold compounds have enjoyed widespread, but occasionally controversial, use in rheumatoid arthritis since the 1920s. This overview examines the data from controlled trials and longer-term observational studies. We conclude that gold is equivalent to other widely used second-line agents in terms of efficacy. Toxicity profiles are similar, apart from methotrcxate. It is most efficacious and toxic in the first 2 yr of treatment. There appears to be a dose-response relationship for both efficacy and toxicity. Gold is one of the few agents that decreases the rate of progression of erosions (RR 0.38, 95% CI 0.23–0.64). Gold compounds, therefore, have a definite place in the rheumatologist's armamentarium, but further research is required to determine optimal monitoring regimes as well as the role of maintenance therapy and combination therapy.
Url:
DOI: 10.1093/rheumatology/35.11.1154
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E75
- to stream Istex, to step Curation: 000E75
- to stream Istex, to step Checkpoint: 001785
- to stream Main, to step Merge: 002A49
- to stream Main, to step Curation: 002997
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>INJECTABLE GOLD COMPOUNDS: AN OVERVIEW</title><author><name sortKey="Jones, G" sort="Jones, G" uniqKey="Jones G" first="G." last="Jones">G. Jones</name></author><author><name sortKey="Brooks, P M" sort="Brooks, P M" uniqKey="Brooks P" first="P. M." last="Brooks">P. M. Brooks</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:658DF435DF395779DB201C9F0759635ED7B0B57D</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1093/rheumatology/35.11.1154</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-LZ1LTG94-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E75</idno><idno type="wicri:Area/Istex/Curation">000E75</idno><idno type="wicri:Area/Istex/Checkpoint">001785</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001785</idno><idno type="wicri:doubleKey">1462-0324:1996:Jones G:injectable:gold:compounds</idno><idno type="wicri:Area/Main/Merge">002A49</idno><idno type="wicri:Area/Main/Curation">002997</idno><idno type="wicri:Area/Main/Exploration">002997</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">INJECTABLE GOLD COMPOUNDS: AN OVERVIEW</title><author><name sortKey="Jones, G" sort="Jones, G" uniqKey="Jones G" first="G." last="Jones">G. Jones</name><affiliation><wicri:noCountry code="subField">7001</wicri:noCountry></affiliation></author><author><name sortKey="Brooks, P M" sort="Brooks, P M" uniqKey="Brooks P" first="P. M." last="Brooks">P. M. Brooks</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincents Hospital Victoria Street, Darlinghurst, NSW 2010</wicri:regionArea><wicri:noRegion>NSW 2010</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Rheumatology</title><idno type="eISSN">1462-0332</idno><idno type="ISSN">1462-0324</idno><imprint><publisher>Oxford University Press</publisher><date when="1996-11">1996</date><biblScope unit="vol">35</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1154">1154</biblScope><biblScope unit="page" to="1158">1158</biblScope></imprint><idno type="ISSN">1462-0324</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-0324</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Injectable gold compounds have enjoyed widespread, but occasionally controversial, use in rheumatoid arthritis since the 1920s. This overview examines the data from controlled trials and longer-term observational studies. We conclude that gold is equivalent to other widely used second-line agents in terms of efficacy. Toxicity profiles are similar, apart from methotrcxate. It is most efficacious and toxic in the first 2 yr of treatment. There appears to be a dose-response relationship for both efficacy and toxicity. Gold is one of the few agents that decreases the rate of progression of erosions (RR 0.38, 95% CI 0.23–0.64). Gold compounds, therefore, have a definite place in the rheumatologist's armamentarium, but further research is required to determine optimal monitoring regimes as well as the role of maintenance therapy and combination therapy.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Jones, G" sort="Jones, G" uniqKey="Jones G" first="G." last="Jones">G. Jones</name></noCountry><country name="Australie"><noRegion><name sortKey="Brooks, P M" sort="Brooks, P M" uniqKey="Brooks P" first="P. M." last="Brooks">P. M. Brooks</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002997 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002997 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:658DF435DF395779DB201C9F0759635ED7B0B57D
|texte= INJECTABLE GOLD COMPOUNDS: AN OVERVIEW
}}
| This area was generated with Dilib version V0.6.33. |  |